Journal: Acta Biochimica et Biophysica Sinica

Article Title: PDGFC secreted by cancer-associated fibroblasts promotes epithelial-mesenchymal transition and immunosuppression in lung adenocarcinoma

doi: 10.3724/abbs.2025042

Figure Lengend Snippet: CAF-derived PDGFC induces EMT in LUAD cells via the PDGFRA-MAPK-ERK signaling pathway (A) Western blot analysis of E-cadherin expression in A549 cells treated with CAF-CM with or without PDGFRA kinase inhibitor 1. (B) Western blot analysis of vimentin expression in A549 cells treated with CAF-CM with or without PDGFRA kinase inhibitor 1. (C) Western blot analysis of E-cadherin expression in A549 cells treated with NF-CM, CAF-CM, rhPDGFCC, CAF-CM + SCH77298 or rhPDGFCC + SCH77298 . (D) Western blot analysis of vimentin expression in A549 cells treated with NF-CM, CAF-CM, rhPDGFCC, CAF-CM + SCH77298 or rhPDGFCC + SCH77298 . (E) Western blot analysis of PDGFRA expression in A549 cells treated with NF-CM, CAF-CM or rhPDGFCC. (F) Western blot analysis of p-ERK and ERK in A549 cells treated with NF-CM, CAF-CM or rhPDGFCC. (G) Western blot analysis of MMP2 expression in A549 cells treated with NF-CM, CAF-CM, rhPDGFCC, CAF-CM + SCH77298 or rhPDGFCC+ SCH77298 . Data are expressed as the mean ± SD, n ≥ 3. *P < 0.05, **P < 0.01, ***P < 0.001.

Article Snippet: The additional reagents used in this study included recombinant human PDGFCC (rhPDGFCC, 20 nM; (MedChemExpress, Monmouth Junction, USA), SCH772984 (5 μM; Selleckchem, Houston, USA) and PDGFRA kinase inhibitor 1 (0.2 μM; MedChemExpress).

Techniques: Derivative Assay, Western Blot, Expressing

Journal: Anesthesiology

Article Title: Platelet-derived Growth Factor Receptor-α Induces Contraction Knots and Inflammatory Pain–like Behavior in a Rat Model of Myofascial Trigger Points

doi: 10.1097/ALN.0000000000005167

Figure Lengend Snippet: Receptor tyrosine kinases (RTKs) expression profiles of myofascial trigger points (MTrPs) tissue derived from upper trapezius muscle of myofascial pain syndrome (MPS) patients and control groups. ( A ) The upregulated RTKs members were validated by microarray analysis. MPS group = 11, Con group = 7. Platelet-derived growth factor receptor-α (PDGFR-α): Con, 879 ± 83.08; 95% CI, 802.2–955.8 versus MPS, 1,060 ± 96.84; 95% CI, 994.9–1,125; units, fluorescent value; mean ± SD; P < 0.001. PDGFR-β: Con, 338.8 ± 47.96; 95% CI, 294.5–383.2 versus MPS, 308.4 ± 51.67; 95% CI, 273.7–343.1; units, fluorescent value; mean ± SD; P > 0.05. ( B ) Representative microscopic images showing morphology of muscle fibers in different groups. The morphology of MTrPs showed that annular or enlarged muscle fibers ( yellow arrows ) of different sizes with centralized nuclei in cross-sectional spaces under microscopy ( yellow arrows ). Scale bars, 20 μm. ( C ) The relationship between pain intensity and expression level of phosphorylated PDGFR-α (p-PDGFR-α) was characterized by a significant positive correlation (r = 0.711; n = 11; P < 0.05). ( D ) Results from enzyme-linked immunosorbent assay (ELISA) showed that the level of serum platelet-derived growth factor-AA (PDGF-AA) was increased. Con, 3.74 ± 0.82; 95% CI, 2.96–4.5; versus MPS, 5.97 ± 0.98; 95% CI, 5.31–6.6; units, ng/ml; mean ± SD; P < 0.001. ( E ) Results from immunohistochemistry (IHC) showed that the expression of PDGF-AA ( yellow arrows ) was upregulated at MTrPs. Scale bars, 20 μm. Con, 1.51 ± 0.33; 95% CI, 1.16–1.85; versus MPS, 10.2 ± 1.57; 95% CI, 8.55–11.85; units, integrated optical density (IOD); mean ± SD; P < 0.001. ( F ) The cross-sectional area of muscle fibers was increased in MPS group. Con, 995.2 ± 166.5; 95% CI, 902.9–1,087; versus MPS, 1,398 ± 124.2; 95% CI, 1,330–1,467; units, μm 2 ; mean ± SD; P < 0.001. ( G ) Representative fluorescence microscopic images showing expression of p-PDGFR-α ( green ) in different groups. Scale bars, 20 μm. Con, 1.00 ± 0.10; 95% CI, 0.89–1.11; versus MPS, 1.44 ± 0.20; 95% CI, 1.23–1.64; units, mean intensity; mean ± SD; P < 0.001. * P < 0.05; ** P < 0.01; *** P < 0.001. ALK, anaplastic lymphoma kinase; EphA, ephrin receptor A; EphB, ephrin receptor B; LTK, leukocyte tyrosine kinase; TRKB, tyrosine kinase receptor B; ZAP70, zeta-chain-associated protein kinase 70.

Article Snippet: Blood samples from patients with MPS were tested for platelet-derived growth factor-AA (PDGF-AA) levels using a human PDGF-AA enzyme-linked immunosorbent assay (ELISA) kit (EK1696, Bosterbio, USA).

Techniques: Expressing, Derivative Assay, Control, Microarray, Microscopy, Enzyme-linked Immunosorbent Assay, Immunohistochemistry, Fluorescence

Journal: Materials Today Bio

Article Title: A 3D radially aligned nanofiber scaffold co-loaded with LL37 mimetic peptide and PDGF-BB for the management of infected chronic wounds

doi: 10.1016/j.mtbio.2024.101237

Figure Lengend Snippet: Preparation and characterization of 3D radially aligned scaffold (RAS) loaded with drug-carrying microspheres . A) Schematic of the preparation processes of the RAS, and W379 antibacterial peptides/PDGF-BB loaded RAS. B) Photographs of the RAS. C) Stereomicroscope images and particle size distributions of 2 % GelMA microspheres, W379 peptides encapsulated GelMA microspheres, and PDGF-BB encapsulated GelMA microspheres. D) The surface morphologies of 2 % GelMA microspheres, W379 peptides encapsulated GelMA microspheres, and PDGF-BB encapsulated GelMA microspheres. E) SEM images show the hybrid RAS was composed of radially aligned PCL nanofibers with microspheres uniformly distributed inside. F) Characterization of PCL nanofiber arrangement in RAS. G) Quantitative pore size analysis at the RAS center and edge area.

Article Snippet: The Human PDGF-BB ELISA Kit(catalog no. EK0956) was ordered from BOSTER (Wuhan, China).

Techniques: Pore Size

Journal: Materials Today Bio

Article Title: A 3D radially aligned nanofiber scaffold co-loaded with LL37 mimetic peptide and PDGF-BB for the management of infected chronic wounds

doi: 10.1016/j.mtbio.2024.101237

Figure Lengend Snippet: The in vivo evaluation of wound healing in diabetic mice . A)The schematic illustrates the establishment of the type-2 diabetes model, the corresponding diabetic skin wound model, and wound management of RAS, RAS + W379, and RAS + W379+PDGF-BB groups, respectively. B) Wound photographs of Blank, RAS, RAS + W379, and RAS + W379+PDGF-BB groups after 0, 3, 7, 14, and 21 days of treatment. C) Traces wound closure at different indicated time points. D) The quantification of wound closure rate at different indicated time points. E) H&E staining of wound area in the Blank, RAS, RAS + W379, and RAS + W379+PDGF-BB groups on day 3, 7, 14, and 21. F) The re-epithelialization rates of the Blank, RAS, RAS + W379, and RAS + W379+PDGF-BB groups on day 3, 7, 14, and 2. *p < 0.05, **p < 0.01, ***p < 0.001.

Article Snippet: The Human PDGF-BB ELISA Kit(catalog no. EK0956) was ordered from BOSTER (Wuhan, China).

Techniques: In Vivo, Staining

Journal: Materials Today Bio

Article Title: A 3D radially aligned nanofiber scaffold co-loaded with LL37 mimetic peptide and PDGF-BB for the management of infected chronic wounds

doi: 10.1016/j.mtbio.2024.101237

Figure Lengend Snippet: Bacterial removal in vivo . A) Giemsa staining in the wound area of the Blank, RAS, RAS + W379, and RAS + W379+PDGF-BB groups after 3 and 7 days of treatment. B) The quantification of detected S.aureus in the wound area of the Blank, RAS, RAS + W379, and RAS + W379+PDGF-BB groups after 3 and 7 days of treatment. C) Bacterial culture photographs of skin tissue infected with S.aureus biofilm during wound healing.

Article Snippet: The Human PDGF-BB ELISA Kit(catalog no. EK0956) was ordered from BOSTER (Wuhan, China).

Techniques: In Vivo, Staining, Infection

Journal: Materials Today Bio

Article Title: A 3D radially aligned nanofiber scaffold co-loaded with LL37 mimetic peptide and PDGF-BB for the management of infected chronic wounds

doi: 10.1016/j.mtbio.2024.101237

Figure Lengend Snippet: The proliferative activities detection during wound healing . A, B) The trichrome staining shows the collagen deposition in the wound central area of the Blank, RAS, RAS + W379, RAS + W379+PDGF-BB groups after 7 days of treatment. C,D) The CD31 immunohistochemical staining of the wound central area in the Blank, RAS, RAS + W379, RAS + W379+PDGF-BB groups after 7 days of treatment. E,F) The K6 immunohistochemical staining of the wound central area in the Blank, RAS, RAS + W379, RAS + W379+PDGF-BB groups after 7 days of treatment. G,H) The Ki67 immunohistochemical staining of the wound central area in the Blank, RAS, RAS + W379, RAS + W379+PDGF-BB groups after 7 days of treatment. I)The schematic illustrates that the treatment of RAS + W379+PDGF-BB is capable of promoting cell recruitment, angiogenesis, collagen deposition, and re-epithelialization based on controlling bacterial infection. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

Article Snippet: The Human PDGF-BB ELISA Kit(catalog no. EK0956) was ordered from BOSTER (Wuhan, China).

Techniques: Staining, Immunohistochemical staining, Infection

Journal: Materials Today Bio

Article Title: A 3D radially aligned nanofiber scaffold co-loaded with LL37 mimetic peptide and PDGF-BB for the management of infected chronic wounds

doi: 10.1016/j.mtbio.2024.101237

Figure Lengend Snippet: Inflammatory responses during wound healing . A,B) The CD45 immunohistochemical staining of the wound central area in the Blank, RAS, RAS + W379 and RAS + W379+PDGF-BB groups after 3 and 7 days of treatment. C,D) The CCR7 immunohistochemical staining of the wound central area in Blank, RAS, RAS + W379 and RAS + W379+PDGF-BB groups after 3 and 7 days of treatment. E,F) The CD206 immunohistochemical staining of the wound central area in the Blank, RAS, RAS + W379 and RAS + W379+PDGF-BB groups after 3 and 7 days of treatment. G) The M1/M2 ratio in the Blank, RAS, RAS + W379 and RAS + W379+PDGF-BB groups. H) Response of W379 antimicrobial peptide to wound inflammatory cells and inflammatory cytokine after bacterial biofilm clearance. *p < 0.05, **p < 0.01, ***p < 0.001.

Article Snippet: The Human PDGF-BB ELISA Kit(catalog no. EK0956) was ordered from BOSTER (Wuhan, China).

Techniques: Immunohistochemical staining, Staining

Journal: Materials Today Bio

Article Title: A 3D radially aligned nanofiber scaffold co-loaded with LL37 mimetic peptide and PDGF-BB for the management of infected chronic wounds

doi: 10.1016/j.mtbio.2024.101237

Figure Lengend Snippet: The expression of inflammatory and anti-inflammatory factors during wound healing . A, B) The Immunohistochemical staining and quantification of IL-6 expression in the wound central area of Blank, RAS, RAS + W379, RAS + W379+PDGF-BB groups after 3 days of treatment. C, D) The immunohistochemical staining and quantification of TNF-α expression in the wound central area of the Blank, RAS, RAS + W379, RAS + W379+PDGF-BB groups after 3 days of treatment. E, F) The immunohistochemical staining and quantification of IL-4 expression in the wound central area of the Blank, RAS, RAS + W379, RAS + W379+PDGF-BB groups after 3 days of treatment. G, H) The immunohistochemical staining and quantification of IL-10 expression in the wound central area of the Blank, RAS, RAS + W379, RAS + W379+PDGF-BB groups after 3 days of treatment. *p < 0.05, **p < 0.01, ***p < 0.001.

Article Snippet: The Human PDGF-BB ELISA Kit(catalog no. EK0956) was ordered from BOSTER (Wuhan, China).

Techniques: Expressing, Immunohistochemical staining, Staining

Journal: Materials Today Bio

Article Title: A 3D radially aligned nanofiber scaffold co-loaded with LL37 mimetic peptide and PDGF-BB for the management of infected chronic wounds

doi: 10.1016/j.mtbio.2024.101237

Figure Lengend Snippet: Histocompatibility test of W379 antibacterial peptide . A, B) Hemolysis test of the RAS, RAS + W379, RAS + W379+PDGF-BB scaffolds. C, D) The viability of L929 cells treated with extraction solution of RAS, RAS + W379, RAS + W379+PDGF-BB scaffolds for 1 and 3 days. E) Histological observations of different organs (heart, liver, spleen, lung, and kidney) after 21 days of treatment in the Blank, RAS + W379+PDGF-BB group.

Article Snippet: The Human PDGF-BB ELISA Kit(catalog no. EK0956) was ordered from BOSTER (Wuhan, China).

Techniques: Extraction